Ultima-Selank — Research Summary
Selank is a synthetic heptapeptide nootropic compound originally developed in Russia for investigating anxiety-related neurological pathways and cognitive enhancement mechanisms. This tuftsin-derived research peptide incorporates the amino acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, representing a modified version of the naturally occurring immunomodulatory tetrapeptide tuftsin with an added C-terminal tripeptide extension. Research laboratories studying neurological pathways frequently investigate Selank for its effects on GABAergic neurotransmission, immunomodulatory properties, and potential neuroprotective mechanisms in controlled experimental settings.
This 5mg research-grade preparation from Ultima Peptides provides investigators at Stroid UK Shop with high-purity material for examining this compound’s unique dual action on both neurological and immunological systems in laboratory models. Researchers studying nootropic peptides often examine Selank alongside other synthetic peptides for comparative analysis of anxiolytic mechanisms and cognitive modulation pathways.
Laboratory Applications
Preclinical research models have examined Selank’s interaction with multiple neurotransmitter systems, particularly its modulation of GABAergic activity and influence on anxiety-related behavioural responses in animal studies. The compound’s structure allows researchers to investigate how tuftsin-derived peptides affect both central nervous system function and peripheral immune responses through IL-6 regulation pathways. Laboratory studies have analysed Selank’s potential neuroprotective properties in stress-induced models, examining its effects on cognitive performance markers and memory consolidation processes.
Investigators studying research peptides frequently examine Selank’s unique pharmacokinetic profile, which demonstrates oral bioavailability in experimental models unlike many traditional peptide compounds. Research protocols often investigate this compound’s duration of action and metabolic stability compared to other nootropic agents. Scientists studying cognitive enhancement mechanisms utilise Selank to examine the relationship between immunomodulation and neurological function, particularly in stress-response pathways and learning paradigms.
Technical Specifications
| Parameter | Value |
|---|---|
| Chemical Name | N-[N-[N-[N-[N-[N-(N-L-Threonyl-L-lysyl)-L-prolyl]-L-arginyl]-L-prolyl]-glycyl]-L-proline |
| CAS Number | 129954-34-3 |
| Molecular Formula | C₃₃H₅₇N₁₁O₉ |
| Molecular Weight | 751.87 g/mol |
| Appearance | White lyophilised powder |
| Storage Temperature | 2-8°C recommended |
| Solubility | Water soluble |
| Research Classification | Nootropic peptide compound |
Research laboratories examining experimental compounds should note that Selank requires careful handling and storage protocols typical of peptide research materials. The compound’s stability profile in solution makes it suitable for various in-vitro and in-vivo research applications when properly reconstituted and stored according to laboratory standards.
Research Compliance Statement
Selank 5mg is supplied by Ultima Peptides exclusively for in-vitro laboratory research and analytical testing applications. This compound is not approved for human consumption, therapeutic use, or any clinical applications. Research institutions must ensure proper handling protocols, appropriate storage conditions, and compliance with local research regulations when studying this experimental nootropic peptide compound in controlled laboratory environments.
